Live Attenuated Vaccines Market Overview
The global live attenuated vaccines market reached USD 7,190.7 million in 2022 and is projected to witness lucrative growth by reaching up to USD 15,520.9 million by 2030. The global live attenuated vaccines market is is expected to exhibit a CAGR of 10.3% during the forecast period (2023-2030). Pricing trend is one of the major factors that boost the market growth.
For instance, the single dose live-attenuated JE vaccine (Imojev) costs around US$ 67.12 (AU$ 100) in Bali when compared to US$ 201.36 (AU$300) in Australia. This is substantially less expensive than the two-dose inactivated/Vero cell-derived JE vaccination currently licensed in North America and Europe. Approximately 60.3 and 26.9% of the travelers were from North America (Canada and the U.S.).
The global live attenuated vaccines market encompasses the sales and distribution of live attenuated vaccines worldwide for various diseases, such as measles, mumps, rubella, yellow fever, influenza, polio, and tuberculosis. These viral vaccines are used to stimulate an immune response and provide immunity against specific infectious diseases.
The viral & bacterial vaccine in the live attenuated vaccines market is expected to grow steadily in the coming years, driven by the increasing focus on immunization programs, rising investments in vaccine research and development, and rising demand from developing countries such as India and China.
Live Attenuated Vaccines Market Dynamics and Trends
The rising prevalence of infectious diseases and different initiatives in promoting immunization drives the market growth
The rising prevalence of infectious diseases is driving the global demand for live attenuated vaccines. For instance, the World Health Organization estimated that 1.6 million people will die from tuberculosis (TB) in 2021 (including 187,000 people with HIV). TB is the 13th largest cause of mortality worldwide and the second leading infectious killer after COVID-19 (behind HIV/AIDS). An estimated 10.6 million individuals will contract tuberculosis (TB) by 2021. Furthermore, government authorities and organizations’ rising emphasis on immunizations supports global market expansion.
Government initiatives to drive market demand
The government is investing extensively in research, development, and infrastructure to deliver better medical care to patients. For instance, in March 2023, the FDA authorized a bivalent Pfizer-BioNTech COVID-19 vaccine as a booster dose for certain children aged 6 months through 4 years. In addition, India’s Finance Minister committed US$ 9.0 billion in funding for vaccine development in the country. The minister stated that the funds would only be utilized for COVID-19 vaccine research and development. According to a Reuters article from April 2023, the U.S. government is investing over US$ 5 billion to speed up the development of new COVID-19 vaccines and treatments, as part of a project called ’Project NextGen’.
High costs associated with the development of live attenuated vaccines
Due to its higher acquisition cost, live attenuated vaccines increased vaccination costs by US$ 7.7 per child compared to trivalent inactivated influenza vaccines. However, compared to trivalent inactivated influenza vaccines, live attenuated vaccines reduced the number of influenza illness cases and lowered the subsequent healthcare for children and productivity losses of parents. Direct and indirect cost offsets saved US$ 15.8 and US$ 37.7 for each vaccinated child. Compared to trivalent inactivated influenza vaccine live attenuated vaccines resulted in a net cost savings of US$ 45.8 per child.

Live Attenuated Vaccines Market Segment Analysis
The global live attenuated vaccines market is segmented based on type, development, end user, and region.
The live animals segment of the global live attenuated vaccine market has the largest market share.
The live animal segment of the global live attenuated vaccine market was valued at US$ 3,085.8 million in 2022 and is expected to exhibit a CAGR of 10.9% over the forecast period to reach US$ 6,141.9 million by 2030. Since vaccine farms were founded to harvest cowpox virus from calves in the late 1800s, animals have been utilized in the manufacturing of human vaccines. In the 20th century, most vaccines were developed using animals by growing pathogens in live animals or using animal cells. Many live attenuated vaccines are developed this way using live animals in vaccine development.

Live Attenuated Vaccines Market Geographical Penetration
The active regional players and increasing infectious diseases in patients
The North America live attenuated vaccines market was valued US$ 2,841.7 million in 2022 and is estimated to reach US$ 6,338.3 million by 2030, exhibiting a CAGR of 10.5% during the forecast period. North America held dominant position in the global live attenuated vaccines market and accounted for the largest market share in the year 2022, due to the rising prevalence of infectious diseases and rising awareness programs by the government towards vaccination. The North America market for live attenuated vaccines includes pharmaceutical companies that manufacture, distribute, and sell these vaccines to healthcare providers and the public. This market is driven by factors such as the high prevalence of infectious diseases, the effectiveness and safety of live attenuated vaccines, and government initiatives promoting vaccination.

Live Attenuated Vaccines Companies and Competitive Landscape
The live attenuated vaccines market is highly competitive with the presence of a large number of existing major players and small vendors. Some of the major players in the global live attenuated vaccines market include Merck & Co., Inc., GlaxoSmithKline plc, Pfizer Inc., Sanofi, Astellas Pharma, CSL Limited, Serum Institute of India Pvt. Ltd., BioDiem, AstraZeneca, Emergent BioSolutions Inc., and Vivaldi Biosciences Inc., among others.

Russia Ukraine Conflict Analysis
The ongoing Ukraine-Russia war has had a significant impact on COVID-19 vaccination efforts in Ukraine, as per the research results. A Bloomberg Law article from March 2022 suggests that the humanitarian crisis caused by the war could worsen the spread of COVID-19 and hamper vaccination efforts across Ukraine. A ReliefWeb article from April 2022 highlights that Russia’s military intervention in Ukraine came at the peak of the COVID-19 pandemic, which has further complicated the situation. A BMJ article from February 2022 suggests that although Russian COVID-19 vaccines are licensed in over 70 countries, their success on the international market could be impeded by the conflict in Ukraine.
Key Developments

  • In May 2022, Jynneos is a live attenuated vaccine being developed by the European biotech firm Bavarian Nordic. Vaccines provide immunity against smallpox and monkeypox. Additionally, antibiotics and hydration therapy are primarily used to treat the symptoms of monkeypox.


Why Purchase the Report?

  • To visualize the global live attenuated vaccines market segmentation based on type, development, end user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous live attenuated vaccines market-level data points with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.


The global live attenuated vaccines market report would provide approximately 53 tables, 51 figures, and 195 Pages.
Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companie